Moderna's COVID-19 vaccine showed a promising result after a trial with mice--the subjects were protected from the viral disease for 13 weeks. The new study found out it could block the novel coronavirus for seven weeks. 

According to Dailymail UK's latest report, the researchers also found that even if the mice were given insufficient immunization doses, the coronavirus infection was still prevented. The medical trial was conducted as Alex Azar, the Health and Human Services Secretary, called the recent COVID-19 inoculation developments "the most historic advances in the development of vaccines," which were conducted for the last two weeks.

Also Read: After COVID-19, Will We Face Mental Health Pandemic? Coronavirus Survivors Suffer From PTSD and Anxiety

The journal Nature published the findings of the new study. The Massachusetts-based Moderna coordinated with the National Institutes of Health to develop their own coronavirus vaccine.

Also Read: Chinese Study Finds COVID-19 Patients Still Suffer From Lung Damage Three Months After Being Discharged

Nature explained that before the novel coronavirus can be controlled, medical experts should first develop a vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 

It also noted that the mRNA-1273 allows the body to enhance its immune system and build a defensive response against the novel coronavirus, by tricking the body to produce some viral proteins.

How mice were not infected even though they're exposed for 13 weeks

The researchers gave the rodents two intramuscular doses, and one-microgram each, three weeks apart. After the mice were injected with Moderna's vaccine, they were introduced to the virus either five weeks or 13 weeks after the second immunization.

The animals were still not infected after they were exposed for one month or even three months. Even the mice which were injected with only one dose of the vaccine were protected from the disease after being exposed for seven weeks without any pathogens found in their lungs.

The vaccination enhances the rodents' CD8 T-cells, helping the animal's body kill the cells infected with viruses and other diseases such as cancer. After the good results, the researchers decided to inject the mice with insufficient COVID-19 vaccine shots.

They were again exposed to the virus to check if vaccine-associated enhanced respiratory disease (VAERD) was developed. There were no signs of lung inflammation or excess mucus production found. The team of researchers concluded that the insufficient vaccine did not enhance the disease.For more updates on other COVID-19 vaccines, always keep your tabs open here at TechTimes.

Also Read: COVID-19 UPDATE: New Study Suggests Jail Can be a Large Source of Virus Infection: Nearby Communities May Also be Infected

This article is owned by TechTimes,

Written by: Giuliano de Leon.

ⓒ 2021 TECHTIMES.com All rights reserved. Do not reproduce without permission.